ANALYSIS OF ASSOCIATION BETWEEN THE CHEMOKINE AND CHEMOKINE RECEPTOR GENES AND ESSENTIAL HYPERTENSION

DOI: https://doi.org/None

Y.R. Timasheva (1), T.R. Nasibullin (1), I.A. Tuktarova (1), V.V. Erdman (1), I.E. Nikolaeva (2), O.E. Mustafina (1) 1 -Institute of Biochemistry and Genetics, Ufa Scientific Centre of Russian Academy of Sciences, Prospekt Oktyabrya, 71, Ufa, Russian Federation, 450054; 2 -Republic Centre for Cardiology, ul. Stepana Kuvyikina, 96, Ufa, Russian Federation, 450106

Introduction. Chemokines are a group of proteins that plays an active role in the regulation of the vascular wall inflammation during the development of essential hypertension. The aim of the study was to investigate an association between essential hypertension and the SNPs in chemokines and their receptor genes CCL2 (rs1024611, -2518A>G), CCR2 (rs1799864, 190A>G, Val64Ile), CCL8 (rs3138035, -571C>T), and CCL18 (rs2015086, -86C>T). Methods. Genotyping of the studied loci was performed in the group comprised of 212 patients with essential hypertension and 314 control subjects using polymerase chain reaction method and restriction analysis. Markov chain Monte-Carlo methods (APSampler) were applied to detect the genotype and allele combinations associated with essential hypertension. Results. The increased risk of the disease was associated with the CCR2*A allele (odds ratio – OR=1,47; р=0,034), and CCR2*A+CCL8*C/T+CCL18*C (OR=15,44; рperm=0,007); CCL2*G/G+CCL8*C+CCL18*C (OR=10,57; рperm=0,042); CCR2*A+CCL8*C+CCL18*C (OR=3,33; рperm=0,008) genotype and allele combinations. The carriers of CCR2*G/G genotype (OR=0,65; рperm=0,029), as well as CCR2*G/G+CCL18*C and CCL2*A+CCR2*G+CCL8*C genotype and allele combinations had reduced risk of essential hypertension (OR=0,6; рperm=0,002 и OR=0,58; рperm=0,042, respectively). Conclusion. Our results suggest that variations in chemokine genes may, in part, explain predisposition to essential hypertension.
Keywords: 
essential hypertension, chemokines, inflammation, genetic polymorphism

Список литературы: 
  1. Lim S.S., Vos T., Flaxman A.D. et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2013; 380 (9859): 2224–60.
  2. Padmanabhan S., Newton-Cheh C., Dominiczak A. F. Genetic basis of blood pressure and hypertension. Trends in Genetics. 2012; 28 (8): 397–408.
  3. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000; 12 (2): 121–7.
  4. Charo I.F., Taubman M.B. Chemokines in the pathogenesis of vascular disease. Circulation research. 2004; 95 (9): 858–66.
  5. Schiffrin E.L. Inflammation, immunity and development of essential hypertension. J. of hypertension. 2014; 32 (2): 228–9.
  6. Favorov A.V., Andreewski T.V., Sudomoina M.A. et al. A Markov chain Monte Carlo technique for identification of combinations of allelic variants underlying complex diseases in humans. Genetics. 2005; 171 (4): 2113–21.
  7. Bose S., Cho J. Role of chemokine CCL2 and it receptor CCR2 in neurodegenerative diseases. Archives of pharmacal research. 2013; 36: 1039–50.
  8. Mantovani A. The chemokine system: redundancy for robust outputs. Immunology today. 1999; 20 (6): 254–7.
  9. Ishibashi M., Hiasa K., Zhao Q. et al. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circulation research. 2004; 94 (9): 1203–10.
  10. Nyquist P.A., Winkler C.A., McKenzie L.M. et al. Single nucleotide polymorphisms in monocyte chemoattractant protein-1 and its receptor act synergistically to increase the risk of carotid atherosclerosis. Cerebrovascular Diseases. 2009; 28 (2): 124–30.
  11. Pham M.H.T., Bonello G.B., Castiblanco J. et al. The rs1024611 regulatory region polymorphism is associated with CCL2 allelic expression imbalance. PloS one. 2012; 7 (11): 49498.
  12. Jemaa R., Ben Ali S., Kallel A. et al. Association between the 2518G/A polymorphism in the monocyte chemoattractant protein-1 (MCP-1) gene and hypertension in Tunisian patients. Clinical Biochemistry. 2009; 42 (1): 34–7.
  13. Huber J., Kiefer F.W., Zeyda M. et al. CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. J. of Clinic. Endocrinology & Metabolism. 2008; 93 (8): 3215–21.
  14. Ma H., Shu Y., Pan S. Polymorphisms of key chemokine genes and survival of non-small cell lung cancer in Chinese. Lung Cancer. 2011; 74 (2): 164–9.
  15. Kraaijeveld A.O., de Jager S.C.A., de Jager W.J. et al. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation. 2007; 116 (17): 1931–41.
  16. Hägg D.A., Olson F.J., Kjelldahl J. et al. Expression of chemokine (C–C motif) ligand 18 in human macrophages and atherosclerotic plaques. Atherosclerosis. 2009; 204 (2): 15–20.
  17. Papaspyridonos M., Smith A., Burnand K.G. et al. Novel candidate genes in unstable areas of human atherosclerotic plaques. Arteriosclerosis, thrombosis, and vascular biology. 2006; 26 (8): 1837–44.
  18. Barlo N.P. Prognostic biomarkers in idiopathic pulmonary fibrosis. – Utrecht University, Geneeskunde Proefschriften. 2013. 160 c.
  19. Schutyser E., Richmond A., Van Damme J. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J. of leukocyte biology. 2005; 78 (1): 14–26.